英文原著

1. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Independent and distinct associations of FABP4 and FABP5 with metabolic parameters in type 2 diabetes mellitus. Front Endocrinol (Lausanne) in press pubmed

2. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovasc Diabetol 2020;19:89. pubmed 

3. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Differential effects of DPP-4 inhibitors, anagliptin and sitagliptin, on PCSK9 levels in patients with type 2 diabetes mellitus who are receiving statin therapy. J Atheroscler Thromb 2020 in press pubmed 

4. Hayashi F et al. Relationship between physical activity/exercise habits and the frequency of new onset of lifestyle-related diseases after the Great East Japan Earthquake among residents in Fukushima: the Fukushima Health Management Survey. J Radiat Res in press


5. Hirai H, Higa M, Morimoto T, Sakuma M, Arasaki O, Nomiyama T, Node K, Ueda S. Shimabukuro M. Dissimilar effects of anagliptin and sitagliptin on lipoprotein subclass in standard or strong statin-treated patients with type 2 diabetes mellitus: a sub-analysis of the REASON Trial. J Clin Med 2020;9:93 pubmed

6. Machii N, Kudo A, Saito H, Tanabe H, Iwasaki M, Hirai H, Masuzaki H, Shimabukuro M. Walking speed is the sole determinant criteria of sarcopenia of mild cognitive impairment in Japanese elderly patients with type 2 diabetes mellitus. J Clin Med 2020;9:2133pubmed

7. Ma E, Ohira T, Sakai A, Yasumura S, Takahashi A, Kazama J, Shimabukuro M, Nakano H, Okazaki K, Maeda M, Yabe H, Suzuki Y, Kamiya K. Dietary patterns associated with cardiometabolic risks in Japan: the Fukushima Health Management Survey, 2011–2015. Nutrients 2020;12:129pubmed

8. Maimaituxun G, Fukuda D, Izaki H, Hirata H, Kanayama H, Masuzaki H, Sata M, Shimabukuro M. Levels of adiponectin expression in peri-renal and subcutaneous adipose tissue and its determinants in human biopsied samples. Front Endocrinol (Lausanne) in press pubmed

9. Maimaituxun G, Kusunose K, Yamada H, Fukuda D, Yagi S, Torii Y, Yamada N, Soeki T, Masuzaki H, Sata M, Shimabukuro M. Deleterious effects of epicardial adipose tissue volume on global longitudinal strain in patients with preserved left ventricular ejection fraction. Front Cardiovasc Med in press 

10. Maimaituxun G, Yamada H, Fukuda D, Yagi S, Kusunose K, Hirata Y, Nishio S, Soeki T, Masuzaki H, Sata M, Shimabukuro M. Association of local epicardial adipose tissue depots and left ventricular diastolic performance in patients with preserved left ventricular ejection fraction. Circ J 2020;84:203-216 pubmed

11. Rahadian A, Fukuda D, Salim HM, Yagi S, Kusunose K, Yamada H, Soeki T, Shimabukuro M, Sata M. Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice. Vasc Pharmacol 2020;124:106632 pubmed

12. Saito H, Tanabe H, Kudo A, Machii N, Higa M, Yamaguchi S, Maimaituxun M, Abe K, Takahashi A, Tanaka T, Asahi K, Masuzaki H, Ohira H, Kazama JJ, Shimabukuro M. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep in press pubmed

13. Saito H, Tanaka K, Iwasaki T, Oda A, Watanabe S, Nakazima A, Aoyagi K, Kanno M, Shimabukuro M, Asahi K, Watanabe T, Kazama JJ. Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease. Sci Rep in press

14. Sakai A, Nakano H, Ohira T, Maeda M, Okazaki K, Takahashi A, Kawasaki Y, Satoh H, Ohtsuru A, Shimabukuro M, Hashimoto S, Hosoya M, Yasumura S, Ohto H, Kamiya K, the Fukushima Health Management Survey Group. Relationship between the prevalence of polycythemia and factors observed in the Mental Health and Lifestyle Survey after the Great East Japan Earthquake. Medicine (Baltimore) 2020;124:106632 pubmed

15. Satoh H, Okazaki K, Ohira T, Sakai A, Hosoya M, Yasumura S, Kawasaki Y, Hashimoto K, Ohtsuru A, Takahashi A, Watanabe K, Shimabukuro M, Kazama JJ, Hashimoto S, Ohira H, Ohto H, Kamiya K, the Fukushima Health Management Survey Group. Relationship between risk of hyper- low-density lipoprotein cholesterolemia and evacuation after the Great East Japan Earthquake. J Epidemiol in press

16. Tanabe H, Saito H, Kudo A, Machii N, Hirai H, Maimaituxun G, Tanaka K, Masuzaki H, Watanabe T, Asahi K, Kazama JJ, Shimabukuro M. Factors associated with risk of diabetic complications in novel cluster-based diabetes subgroups: a japanese retrospective cohort study. J Clin Med 2020;9:2083 pubmed 

17. Tanabe H, Saito H, Machii N, Kudo A, Tanaka K, Asahi K, Kazama JJ. Shimabukuro M. Burden of undiagnosed type 2 diabetes in diabetic kidney disease: a japanese retrospective cohort study. J Clin Med 2020;9:2028 pubmed

18. Tanaka, A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima K,  Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M, Ueda S, Higashi Y, Node K. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: the placebo-controlled double-blind randomized EMBLEM trial. J Diabetes Investig in press pubmed

19. Tanaka A, Shimabukuro M, Okada Y, Sugimoto K, Kurozumi A, Torimoto K, Hirai H, Node K. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial. Cardiovasc Diabetol 2020;19:85 pubmed

20. Tanaka K, ..., Shimabukuro M, Asahi K, Watanabe T, Kazama JJ.  Status of anemia according to underlying renal disease in chronic kidney disease: The Fukushima CKD Cohort. Annals Clin Epidemiol in press

21. Tanaka K, Honda K, Okazaki K; Kazama JJ, Hashimoto S, Ohira T, Sakai A, Yashumura S, Maeda M, Yabe H, Suzuki Y, Hosoya M, Tahakashi A, Nakano H, Yahashi F, Nagao M, Ohira H, Shimabukuro M, Ohto H, Kamiya K. Evacuation after the Great East Japan Earthquake is an independent factor associated with hyperuricemia: the Fukushima Health Management Survey. Nutr Metab Cardiovasc Dis in press

23. Tanaka K, Saito H, Iwasaki T, Oda A, Watanabe S, Kanno M, Kimura H, Shimabukuro M, Asahi K, Watanabe T, Kazama JJ. Association between serum potassium levels and adverse 1 outcomes in chronic kidney disease: The Fukushima CKD Cohort study. Clin Exp Nephrol in press

23. Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Ueda S. Effect of anagliptin versus sitagliptin on inflammatory markers: outcomes from the REASON Trial. Diabetes Metab Syndr Obes in press

24. Yamaguchi S, Abe M, Iseki K, Arakaki T, Arasaki O, Shimabukuro M, Ueda S. Prognostic impact of the early changes in serum chloride level among hospitalized acute heart failure patients: A Retrospective Cohort Study. Circ Rep in press

25. Yamaguchi S, Manabe O, Abe M, Chiba I, Arasaki O, Shimabukuro M. Fractional flow reserve value of reverse redistribution in 201-thallium stress scintigraphy. Vasc Failure in press pubmed

26. Yamaguchi S, Oba K, Higa H, Arasaki O, Shimabukuro M. Age-dependent efficacy of ezetimibe for low-density lipoprotein cholesterol reduction in Japanese patients with or without type 2 diabetes mellitus. J Clin Med 2020;9:1675 pubmed

英文総説

英文症例

和文著書

・齋藤悠、島袋 充生 高浸透圧高血糖状態 糖尿病最新の治療 印刷中

・島袋充生:SGLT2阻害薬を処方する際の禁忌や注意点. ひと味違うSGLT2阻害薬の考え方、使い方 中外医学社; 2020

・島袋充生 Metabolic syndrome and dyslipidemia メタボリックシンドロームと糖尿病(翻訳) The ESC Handbook on Cardiovascular Pharmacotherapy (2 Ed) Edited by Juan Carlos Kaski and Keld Per Kjeldsen 欧州心臓病学会(ESC)心血管薬物療法ハンドブック 日本語翻訳版 Oxford Univ Press, 2020, UK

和文総説

・島袋 充生 心臓脂肪・血管周囲脂肪と心臓血管病 糖尿病プラクティス 2020:37;421-425.

・島袋 充生 【糖尿病患者の心不全を防ぐ! 疾患と治療のキホンと療養指導のコツ】糖尿病薬物療法と心不全 糖尿病ケア 印刷中

・平井裕之、島袋充生「糖尿病患者の心血管病罹患リスクにどう立ち向かうか」糖尿病患者の血糖,血圧,脂質管理はどうする? Heart and View 2020;125:227-230.

・田辺隼人、島袋充生【心腎連関から考える2型糖尿病の治療戦略~SGLT2 阻害薬を中心に~】インスリン抵抗性と心腎連関 月刊糖尿病 印刷中

・山口怜、島袋充生【糖尿病専門医に必要な心不全の知識update】チアゾリジン薬と心不全 月刊 『糖尿病・内分泌代謝科』 印刷中

・山崎 聡, 尾形 絵美, 岡本 士毅, 島袋 充生, 益崎 裕章【高血圧診療Update-「高血圧治療ガイドライン2019」で何が変わるのか?】他疾患を合併する高血圧 肥満症・メタボリックシンドローム 内科 2020;125:227-230.

・山崎 聡, 尾形 絵美, 岡本 士毅, 島袋 充生, 益崎 裕章【新しい時代の高血圧診療】合併症を伴う高血圧の治療 脂質異常症・肥満症・高尿酸血症 他疾患を合併する高血圧 肥満症・メタボリックシンドローム 臨牀と研究2020:97;72-77.

・山崎 聡, 島袋 充生, 益崎 裕章 糖・脂質代謝領域における高血圧学の現状と展望 日本臨床 増刊号 高血圧学 2020 印刷中

和文症例

・伊藤 裕平, 神宮字 伸哉, 佐藤 祐介, 佐藤 拓, 村上 友太, 藤井 正純, 佐久間 潤, 岩崎 麻里子, 工藤 明宏, 島袋 充生, 喜古 雄一郎, 岡田 正康, 齋藤 清 腫瘍の局在診断に苦慮した症候性ACTHおよびGH産生性重複下垂体腺腫の1例 Neurological Surgery 2020:48:253-260

国際学会


国内学会